Q2 Earnings Estimate for ACAD Issued By Leerink Partnrs

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share estimates for ACADIA Pharmaceuticals in a report released on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings of $0.16 per share for the quarter, down from their previous forecast of $0.21. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2025 earnings at $0.55 EPS and FY2029 earnings at $2.15 EPS.

Several other research firms have also issued reports on ACAD. UBS Group decreased their price target on shares of ACADIA Pharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Monday, April 28th. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Tuesday, April 8th. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. StockNews.com cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price target on the stock. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.70.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ:ACAD opened at $17.20 on Monday. ACADIA Pharmaceuticals has a 12 month low of $13.40 and a 12 month high of $20.68. The stock has a market cap of $2.88 billion, a price-to-earnings ratio of 22.05 and a beta of 0.47. The stock’s 50 day moving average price is $15.81 and its 200 day moving average price is $17.00.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.10 by $0.01. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The firm had revenue of $244.32 million for the quarter, compared to analysts’ expectations of $239.32 million. During the same quarter in the previous year, the company earned $0.10 earnings per share. The firm’s quarterly revenue was up 18.7% compared to the same quarter last year.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, Director Elizabeth A. Garofalo sold 4,919 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the transaction, the director now owns 17,595 shares of the company’s stock, valued at $320,756.85. The trade was a 21.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Mark C. Schneyer sold 2,708 shares of the business’s stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of $14.82, for a total transaction of $40,132.56. Following the transaction, the executive vice president now directly owns 59,456 shares of the company’s stock, valued at approximately $881,137.92. This represents a 4.36% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,994 shares of company stock valued at $313,131. Insiders own 26.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ACAD. Northern Trust Corp increased its holdings in shares of ACADIA Pharmaceuticals by 11.6% during the 1st quarter. Northern Trust Corp now owns 1,375,213 shares of the biopharmaceutical company’s stock worth $22,842,000 after purchasing an additional 142,847 shares during the period. American Century Companies Inc. grew its stake in ACADIA Pharmaceuticals by 1,055.8% during the first quarter. American Century Companies Inc. now owns 1,632,749 shares of the biopharmaceutical company’s stock worth $27,120,000 after buying an additional 1,491,484 shares during the last quarter. Fox Run Management L.L.C. grew its stake in ACADIA Pharmaceuticals by 25.6% during the first quarter. Fox Run Management L.L.C. now owns 31,938 shares of the biopharmaceutical company’s stock worth $530,000 after buying an additional 6,516 shares during the last quarter. E Fund Management Co. Ltd. grew its stake in ACADIA Pharmaceuticals by 76.1% during the first quarter. E Fund Management Co. Ltd. now owns 18,718 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 8,090 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in ACADIA Pharmaceuticals by 22.0% during the first quarter. Russell Investments Group Ltd. now owns 241,323 shares of the biopharmaceutical company’s stock worth $4,008,000 after buying an additional 43,523 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.